Adjuvant therapy in pancreatic cancer

Digestive Diseases

Volumn 28, Issue 4-5, 2010, Pages 684-692

  Thomas, Amy ^a   Dajani, Khaled ^a   Neoptolemos, John P ^a   Ghaneh, Paula ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Adjuvant chemotherapy; Meta analysis; Pancreatic cancer

Indexed keywords

DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MITOMYCIN C;

BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; INTRAOPERATIVE RADIOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; QUALITY CONTROL; RADIATION DOSE FRACTIONATION; RISK REDUCTION;

CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HUMANS; META-ANALYSIS AS TOPIC; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 78649346438     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320099     Document Type: Conference Paper

References (45)

1. CancerStats. http://info.cancerresearchuk. org/cancerstats/.
2. Cress RD, Yin DX, Clarke L, Bold R, Holly EA: Survival among patients with adenocarcinoma of the pancreas: a populationbased study (United States). Cancer Causes Control 2006; 17: 403-409.
3. Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R, Neoptolemos JP: Current standards of surgery for pancreatic cancer. Br J Surg 2004; 91:1410-1427.
4. Sperti C, Pasquali C, et al: Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997; 21: 195 -2 00. (Pubitemid 27053441)
5. Fortner JG, Klimstra DS, Senie RT, Maclean BJ: Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg 1996; 223:147-153.
6. Müller MW, Friess H, Kleeff J, Dahmen R, Wagner M, Hinz U, Breisch-Girbig D, Ceyhan GO, Büchler MW: Is there still a role for total pancreatectomy? Ann Surg 2007; 246: 966-974, discussion 974-965.
7. Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, Kloppel G, Dhaene K, Michelassi F: Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas - a multicenter, prospective, randomized study. Ann Surg 1998; 228: 508-514.
8. Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Ca mpbel l KA, Sauter PK, Colema n J, Abra ms RA, Hruban RH: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002; 236: 355-366, discussion 366-358.
9. Farnell MB, Pearson RK, Sarr MG, DiMagno EP, Burgart LJ, Dahl TR, Foster N, Sargent DJ: A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005; 138: 618 - 628, discussion 628-630.
10. Haslam JB, Cavanaugh PJ, Stroup SL: Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas. Cancer 1973; 32:1341-1345.
11. Moertel CG, Childs DS, Reitemeier RJ, Colby MY, Holbrook MA: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969; 2:865-867.
12. Fossati V, Cattaneo GM, et al: The role of intraoperative therapy by electron beam and combination of adjuvant chemotherapy and external radiotherapy in carcinoma of the pancreas. Tumori 1995; 81 : 23-31.
13. Zerbi A, Fossati V, et al: Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer. Cancer 1994; 73: 2930-2935.
14. Hiraoka T, Uchino R, et al: Combination of intraoperative radiation with resection of cancer of the pancreas. Int J Pancreatol 1990; 7:201-207.
15. Coquard R, Ayzac L, et al: Intraoperative radiotherapy in resected pancreatic cancer: feasibility and results. Radiother Oncol 1997; 44: 271-275.
16. Reni M, Panucci MG, et al: Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2001; 50:651-658.
17. Sindelar W, Kinsella T: Randomised trial of intraoperative radiotherapy in resected carcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1986; 12(suppl 1):148.
18. Sindelar W, Kinsella T: Studies of intraoperative radiotherapy in carcinoma of the pancreas. Ann Oncol 1999; 10(suppl 4):226-230.
19. Kalser MH, Ellenberg SS: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120:899-903.
20. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776-782, discussion 782-774.
21. Smeenk HG, van Eijck CH, Hop WC, Erdmann J, Tran KC, Debois M, van Cutsem E, van Dekken H, Klinkenbijl JH, Jeekel J: Longterm survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: longterm results of EORTC trial 40891. Ann Surg 2007; 246: 734-740.
22. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman J, Sauter PK, Pitt HA, Lillemoe KD, Cameron JL: Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, singleinstitut ion experience. Ann Surg 1997; 225: 621- 633, discussion 633-636.
23. Neoptolemos J, Stocken DD, Freiss H, Bassi C, Du nn J, Hickey H, Beger H- G, Fer na nde z-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler M: A randomised trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210.
24. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Büchler MW: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358: 1576-1585.
25. Twombly R: Adjuvant chemoradiation for pancreatic cancer: few good data, much debate. J Natl Cancer Inst 2008; 100:1670-1671.
26. Corsini MM, Miller RC, et al: Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol 2008; 26: 3511-3516.
27. Artinyan A, Hellan M, et al: Improved survival with adjuvant externalbeam radiation therapy in lymph nodenegative pancreatic cancer. Cancer 2008;112:34-42.
28. Greco JA, Castaldo ET, et al: Survival benefit with adjuvant radiation in surgically resected pancreatic cancer (abstract 109). ASCO Gastrointestinal Cancers Symposium Proceedings, Chicago, 2007.
29. Regine WF, Winter KW, et al: RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs, gemcitabine (G) for resected pancreatic adenocarcinoma. 2006 ASCO Annual Meeting Proceedings. J Clin Oncol 2006; 23(18S):4 0 07.
30. Burris HA 3rd, Moore MJ, et al: Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
31. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073-1081.
32. Bakkevold KE, Arnesjo B, Dahl O, Kambestad B: Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater - results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993; 29A:698-703.
33. Takada T, Amano H, et al: Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002; 95:1685-1695.
34. Kosuge T, Kiuchi T, et al: A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 2006; 36: 159-165.
35. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H: Adju va nt che mot h er apy w it h ge mc ita bi ne vs observation in patients undergoing curativeintent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277.
36. Riess H, Neuhaus P, Post S, Gellert K, Ridwelski K, Schramm H, Zuelke C, Fahlke J, Langrehr J, Oettle H: CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC); in 33rd European-Societyfor-Medical-Oncology Congress; 2008 Sep 12-16. Stockholm, Oxford Univ Press, 2008, pp 45-46.
37. Neoptolemos JP, Stocken DD, Smith CT, Bassi C, Ghaneh P, Owen E, Moore M, Padbury R, Doi R, Smith D, Buchler MW, European Study Grp Pancreatic C: Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and-3(v1) trials. Br J Cancer 2009; 10 0 : 246-250.
38. Ueno H, Kosuge T, et al. : Arandomised phase III trial comparing gemcitabine with surgeryonly in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009; 101: 908-915.
39. Richter J, Saif MW: Updates in adjuvant therapy in pancreatic cancer: gemcitabine and beyond. Highlights from the '2010 ASCO Gastrointestinal Cancers Symposium'. Orlando, FL, USA. January 22-24, 2010. JOP 2010; 11: 14 4-147.
40. Bao PQ, Ramanathan RK, Moser AL, Bahary N, Lembersky BC, Bartlett DL, Hughes SJ, Lee KK, Zeh H III: Phase II trial of adjuvant gemcitabine and erlotinib for resected pancreatic cancer. ASCO GI Cancers Symposium, Orlando, abstract 224.
41. Yamamoto J, Saiura A, et al: Improved survival of leftsided pancreas cancer after surgery. Jpn J Clin Oncol 2010; 40: 530-536.
42. Stocken DD, Buchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Neoptolemos JP: Metaanalysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005; 92: 1372-1381.
43. Boeck S, Ankerst DP, Heinemann V: The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and metaanalysis. Oncology 2007;72:314-321.
44. Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JHG, Bakkevold KE, Takada T, Amano H, Dervenis C, Bassi C, Buchler MW, Neoptolemos JP; Pancreatic Cancer Meta-Analysis Group: Influence of resection margins and treatment on survival in patients with pancreatic cancer - metaanalysis of randomized controlled trials. Arch Surg 2008; 14 3 : 75-83.
45. Farrell JJ, Elsaleh H, Garcia M, et al: Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009;136:187-195.